Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

Share Price is delayed by 15 minutes
Get Live Data
22.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 1.00 (4.545%)
Market Cap: £31.18m
SAR Live PriceLast checked at - London Stock Exchange

Intraday Sareum Share Chart

Corporate update

19 Jun 2008 07:00

RNS Number : 0476X
Sareum Holdings PLC
19 June 2008
 



19 June 2008

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Corporate Update

Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, announced on 2 May 2008, that the Board was undertaking a strategic review to consider how best to take the business forward and create value for shareholders. 

 

On 14 May, the Company announced that as part of the strategic review, the board had implemented a staff restructuring process to reduce its cost base by approximately one third and prepare itself for any potential acquisition or re-financing whilst the future business strategy is under consideration. The restructuring programme has been successfully completed and the Sareum board will continue to review the Company's cost base diligently. In addition, the Company is making progress on a number of fronts and these are described below.

Following announcement of the review on 2 May, Sareum has received expressions of interest in parts or all of its business, particularly its valuable drug discovery programmes, and has received interest in and possible offers to partner, fund, acquire or invest in certain of its programmes or assets. Any transaction resulting from these discussions would lead to an injection of cash into the Company. Initial due diligence is currently being undertaken in respect of several of these discussions. These discussions are at various stages and there is no certainty that any one of them will lead to an offer being made for the Company or any of its assets. The Sareum board continues to actively progress discussions and further announcements will be made as appropriate. 

The Board has concluded, as a result of this review, that the Company should undertake a strategic transaction and it will need to effect a fundraising to enable it to complete such a transaction. In order to facilitate this, the Company will shortly be sending a notice to shareholders convening a general meeting at which shareholders will be asked to give the directors authority to issue further shares for cash. Should the Board decide within a short timescale that strategic transaction is not achievable, the Board will take a decision as to the future of the Company in its present form, as the Company would not be able to continue operations without a significant fundraising.

- Ends-

For further information please contact

Sareum Holdings plc

01223 497700

Tim Mitchell, Chief Executive Officer

 

Buchanan Communications

020 7466 5000

Tim Anderson, Mary-Jane Johnson 

 

Grant Thornton Corporate Finance

020 7383 5100

Philip Secrett, Colin Aaronson

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQVLFFVQBZBBD
Date   Source Headline
9th Feb 20177:00 amRNSNotice of Interim Results
9th Jan 201712:05 pmRNSMilestone Payment from Chk1 Licence Agreement
22nd Dec 20169:47 amRNSResult of General Meeting
15th Dec 201611:38 amRNSResult of AGM
6th Dec 20167:00 amRNSDirectors' Remuneration & General Meeting
29th Nov 20167:00 amRNSSareum to Present at AACR-NCI-EORTC Conference
21st Nov 20167:00 amRNSNotice of AGM
2nd Nov 20167:00 amRNSFinal Results
24th Oct 20167:00 amRNSSuccessful Outcome from TYK2 Feasibility Study
17th Oct 20167:00 amRNSJapan and Singapore Patent Grants
27th Sep 201612:02 pmRNSLicence agreement for Chk1 Inhibitor CCT245737
3rd Aug 20167:00 amRNSChina & HK Patent Grants for Sareum's Aurora+FLT3
28th Jul 20167:00 amRNSMovement in share price
23rd May 201612:00 pmRNSClinical Trials CHK1 Inhibitor CCT245737 to Open
17th May 20167:00 amRNSChange of Director
5th Apr 201610:38 amRNSCHK1 Approved for Clinical Trials
24th Mar 201611:54 amRNSPlacing
14th Mar 20167:00 amRNSIssue of Options
10th Mar 201612:55 pmRNSShare price movement
24th Feb 20167:01 amRNSResearch & Co-Development Collaborations Update
24th Feb 20167:00 amRNSHalf-Yearly Results for December 2015
1st Feb 20167:00 amRNSCHK1 Clinical Trial Application Submissions
15th Dec 201511:20 amRNSResult of AGM
15th Dec 20157:00 amRNSCHK1 Clinical Trial Applications
13th Nov 201510:15 amRNSNotice of AGM
26th Oct 20157:00 amRNSFinal Results
15th Sep 20157:00 amRNSUS and European Patent Grants for Aurora+FLT3
23rd Jul 20157:00 amRNSCHK1 Research Update
17th Jun 20157:00 amRNSFunding Award from Innovate UK
28th May 20157:00 amRNSPlacing
21st May 20157:00 amRNSSareum Launches New Website
12th May 20157:01 amRNSSareum to Present at BioTrinity 2015
7th May 20157:00 amRNSEarly Conclusion of Equity Swap Agreement
16th Mar 20157:00 amRNSChange of Adviser
20th Jan 20157:00 amRNSFurther US Patent Grant for Kinase Inhibitors
13th Oct 20148:20 amRNSHolding(s) in Company
1st Oct 20147:00 amRNSPromising Step in Psoriasis Drug Development
22nd Sep 20147:00 amRNSCHK1 Patent Update
2nd Jul 20147:00 amRNSJapanese Patent Grant for Kinase Inhibitors
30th Jun 20142:15 pmRNSTotal Voting Rights
26th Jun 20147:00 amRNSPreclinical Proof of Concept in TYK2 Programme
22nd Jan 20147:00 amRNSCHK1 Patent Update
25th Oct 20137:00 amRNSSareum to Present at London Investor Show
10th Sep 20127:00 amRNSFinancing
7th Aug 20121:20 pmRNSStmnt re Share Price Movement
7th Jun 20127:00 amRNSPlacing
6th Jun 20127:00 amRNSPlacing
30th Jan 20127:00 amRNSNotice of Results
4th Nov 20112:29 pmRNSReport & Accounts & Notice of AGM Available
3rd Aug 20107:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.